We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
When Progressive Disease Does Not Mean Treatment Failure: Reconsidering the Criteria for Progression.
- Authors
Oxnard, Geoffrey R.; Morris, Michael J.; Hodi, E. Stephen; Baker, Laurence H.; Kris, Mark G.; Venook, Alan P.; Schwartz, Lawrence H.
- Abstract
Although progression-based endpoints, such as progression-free survival, are often key clinical trial endpoints for anticancer agents, the clinical meaning of "objective progression" is much less certain. As scrutiny of progression-based endpoints in clinical trials increases, it should be remembered that the Response Evaluation Criteria In Solid Tumors (RECIST) progression criteria were not developed as a surrogate for survival. Now that progression-free survival has come to be an increasingly important trial endpoint, the criteria that define progression deserve critical evaluation to determine whether alternate definitions of progression might facilitate the development of stronger surrogate endpoints and more meaningful trial results. In this commentary, we review the genesis of the criteria for progression, highlight recent data that question their value as a marker of treatment failure, and advocate for several research strategies that could lay the groundwork for a clinically validated definition of disease progression in solid tumor oncology.
- Subjects
DISEASE progression; ANTINEOPLASTIC agents; CANCER treatment; CLINICAL trials; ONCOLOGY
- Publication
JNCI: Journal of the National Cancer Institute, 2012, Vol 104, Issue 20, p1534
- ISSN
0027-8874
- Publication type
Article
- DOI
10.1093/jnci/djs353